출판 : MarketsandMarkets（마켓츠앤마켓츠）출판년월 : 2022년06월
감염병 진단 시장 : 제품(시약, 키트, 장비, 소프트웨어), 검사 유형(랩, POC), 질병(COVID-19, 인플루엔자, HAI, HIV, HPV), 기술(면역 진단, NGS, INAAT, PCR), 최종 사용자(병원 , 실험실) – 2027년까지의 세계 예측
Infectious Disease Diagnostics Market by Product (Reagents, Kits, Instrument, Software), Test Type (Lab, POC), Disease (COVID-19, Flu, HAIs, HIV, HPV), Technology (Immunodiagnostics, NGS, INAAT, PCR), End User (Hospitals, Labs) – Global Forecast to 2027
| 페이지수 | |
| 도표수 | |
| 구성 | 영문조사보고서 |
| 가격 |
The global infectious disease diagnostics market size is projected to reach USD 33.1 billion by 2027 from USD 35.5 billion in 2022, at a -1.4% CAGR.Market is driven by factors such as indication of infectious diseases, growing trend in POC testing and rising technological advancements.
전 세계 감염병 진단 시장 규모는 2022년 355억 달러에서 2027년까지 331억 달러로 CAGR -1.4%로 성장할 것으로 예상됩니다.
시장은 전염병의 징후, POC 테스트의 추세 증가 및 기술 발전의 증가와 같은 요인에 의해 주도됩니다.
However,an unfavorable reimbursement scenario is expected to limit market growth to a certain extent in the forecasted years.
“The reagents, kits, and consumablesaccounted for the largest market sharein theinfectious disease diagnostics market, byproduct& service, during the forecast period”
The infectious disease diagnostics market is segmented into reagents, kits, and consumables; instruments; and software & services. The reagents, kits, and consumables segment accounted for the largest market share in the infectious disease diagnostics market in 2021. Major factors driving the growth of this segment include the increasing number of infectious disease diagnostic tests carried out, the growing need for more reliable, more specific, and faster detection of infectious diseases in the early stages. This is the largest and fastest-growing product segment in the infectious disease diagnostics market. Also, the frequent need for reagents & kits makes it a recurrent cost.
“Mosquito-borne diseasessegment accounted for the highest CAGR”
Based on the disease type, the infectious disease diagnostics market is segmented into COVID-19, HIV, Hospital-acquired infections, hepatitis, Chlamydia trachomatis, Neisseria Gonorrhea, HPV, Tuberculosis, influenza, syphilis, mosquito-borne diseases and other infectious diseases. In 2021, the mosquito-borne diseasessegment accounted for the highest CAGR.
“Diagnostic Laboratoriessegment accounted for the largest market share”
Based on end-users, the infectious disease diagnostics market is segmented into diagnostic laboratories, hospitals & clinics, academic research institutes, and other end users. The diagnostic laboratories segment accounted for the largest market share in 2021. This can be attributed to the development of complex and highly specialized tests in infectious disease diagnostics and strengthening healthcare infrastructures for efficient disease diagnosis and treatment.
The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 – 40%, Tier 2 – 30%,and Tier 3 -30%
• By Designation: C-level – 27%, D-level – 18%, and Others – 55%
• By Region: North America -51%, Europe – 21%, Asia Pacific – 18%, Latin America – 6%, and the Middle East & Africa – 4%
Lits of Companies Profiled in the Report:
• Abbott Laboratories (US)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• bioMérieux SA (France)
• Thermo Fisher Scientific Inc. (US)
• Danaher Corporation (US)
• QuidelCorporation(US)
• Hologic, Inc. (US)
• PerkinElmer Inc. (US)
• Bio-Rad Laboratories, Inc. (US)
• QIAGEN (Netherlands)
• Siemens Healthineers AG (Germany)
• Becton, Dickinson and Company (US)
• DiaSorin S.p.A (Italy)
• Grifols S.A. (Spain)
• Sysmex Corporation (Japan)
• Seegene Inc. (South Korea)
• Ortho Clinical Diagnostics (US)
• Genetic Signatures (Australia)
• Meridian Bioscience (US)
• OraSure Technologies (US)
• Trinity Biotech Plc. (Ireland)
• Chembio Diagnostic Systems (US)
• Co-Diagnostics (US)
• ELITechGroup (France)
• Epitope Diagnostics (US)
• Trivitron Healthcare (India)
• Meril Life Sciences Pvt. Ltd. (India)
• InBios International (US)
• Uniogen Oy (Finland)
• Vela Diagnostics (Singapore)
Research Coverage:
This report provides a detailed picture of the global infectious disease diagnostics market. It aims at estimating the size and future growth potential of the market across different segments, such as product& service, test of testing, technology,disease type, end user, and region. The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall infectious disease diagnostics market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, challenges, and opportunities.
목차
TABLE OF CONTENTS
1 INTRODUCTION (Page No. – 32)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKETS SCOPE
1.3.1 MARKETS COVERED
FIGURE 1 INFECTIOUS DISEASE DIAGNOSTICS MARKET SEGMENTATION
FIGURE 2 MARKETS COVERED – BY REGION
1.3.2 INFECTIOUS DISEASE DIAGNOSTICS MARKET: YEARS CONSIDERED
FIGURE 3 YEARS CONSIDERED
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. – 37)
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
FIGURE 4 INFECTIOUS DISEASE DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY
2.2.1 SECONDARY DATA
2.2.1.1 Primary sources
2.2.1.2 Key data from primary sources
2.2.2 PRIMARY DATA
2.2.2.1 Breakdown of primary interviews
2.2.2.2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS
2.2.2.3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2.2.4 MARKET SIZE ESTIMATION
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY SIDE AND DEMAND SIDE PARTICIPANTS
FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.3 MARKET SIZE ESTIMATION
2.3.1 BOTTOM-UP APPROACH
2.3.1.1 Growth forecast
FIGURE 7 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
2.3.1.2 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS
2.3.1.3 TOP-DOWN APPROACH
2.3.1.4 INFECTIOUS DISEASE DIAGNOSTICS MARKET: TOP-DOWN APPROACH
FIGURE 8 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS
2.3.2 TOP-DOWN APPROACH
FIGURE 9 INFECTIOUS DISEASE DIAGNOSTICS MARKET: TOP-DOWN APPROACH
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 10 DATA TRIANGULATION METHODOLOGY
2.5 MARKET SHARE
2.6 STUDY ASSUMPTIONS
2.7 LIMITATIONS
2.8 GROWTH RATE ASSUMPTIONS
2.9 RISK ASSESSMENT
2.9.1 RISK ASSESSMENT: INFECTIOUS DISEASE DIAGNOSTICS MARKET
3 EXECUTIVE SUMMARY (Page No. – 50)
FIGURE 11 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
FIGURE 12 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
FIGURE 13 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022 VS. 2027 (USD MILLION)
FIGURE 14 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)
FIGURE 15 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2022 VS. 2027 (USD MILLION)
4 PREMIUM INSIGHTS (Page No. – 54)
4.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET OVERVIEW
FIGURE 16 RISING ADOPTION OF POC DIAGNOSTICS TO SUPPORT MARKET GROWTH DURING FORECAST PERIOD
4.2 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
FIGURE 17 REAGENTS, KITS, AND CONSUMABLES SEGMENT TO COMMAND LARGEST MARKET SHARE BY PRODUCT & SERVICE IN 2022
4.3 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)
FIGURE 18 IMMUNODIAGNOSTICS TO DOMINATE MARKET DURING FORECAST PERIOD
4.4 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2022 VS. 2027
FIGURE 19 DIAGNOSTIC LABORATORIES TO DOMINATE END USER MARKET
5 MARKET OVERVIEW (Page No. – 57)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 20 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising technological advancements in infectious disease diagnostics
5.2.1.2 Shift in focus from centralized laboratories to decentralized POC testing
5.2.1.3 RESTRAINTS
5.2.1.4 Unfavorable reimbursement scenario
5.2.1.5 OPPORTUNITIES
5.2.2 RESTRAINTS
5.2.2.1 CHALLENGES
5.2.3 OPPORTUNITIES
5.2.3.1 Operational barriers
5.2.4 CHALLENGES
5.2.4.1 PRICING ANALYSIS
5.2.4.2 INDICATIVE PRICING MODEL ANALYSIS
5.2.5 IMPACT OF COVID-19 ON INFECTIOUS DISEASE DIAGNOSTICS MARKET
5.3 PRICING ANALYSIS
5.3.1 INDICATIVE PRICING MODEL ANALYSIS
TABLE 1 INDICATIVE PRICE OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS (2022)
5.4 PATENT ANALYSIS
FIGURE 21 LIST OF MAJOR PATENTS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES
5.4.1 LIST OF MAJOR PATENTS
5.5 VALUE CHAIN ANALYSIS
FIGURE 22 VALUE CHAIN ANALYSIS: MAJOR VALUE IS ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
5.6 SUPPLY CHAIN ANALYSIS
FIGURE 23 INFECTIOUS DISEASE DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM MARKET MAP
FIGURE 24 INFECTIOUS DISEASE DIAGNOSTICS MARKET: ECOSYSTEM MARKET MAP
5.7.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 2 INFECTIOUS DISEASE DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
5.8.1 THREAT FROM NEW ENTRANTS
5.8.2 THREAT FROM SUBSTITUTES
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 BARGAINING POWER OF SUPPLIERS
5.8.5 DEGREE OF COMPETITION
5.9 PESTLE ANALYSIS
5.10 REGULATORY LANDSCAPE
5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 3 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 4 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 5 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 6 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.10.2 NORTH AMERICA
5.10.2.1 EUROPE: CLASSIFICATION OF DEVICES
5.10.2.2 ASIA PACIFIC
5.10.3 EUROPE
TABLE 7 EUROPE: CLASSIFICATION OF DEVICES
5.10.4 ASIA PACIFIC
5.10.4.1 LATIN AMERICA
5.10.4.2 Brazil
5.10.4.3 Mexico
5.10.5 LATIN AMERICA
5.10.5.1 AFRICA
5.10.5.2 TRADE ANALYSIS
5.10.6 MIDDLE EAST
5.10.7 AFRICA
5.11 TRADE ANALYSIS
5.11.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
TABLE 8 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2017–2021 (USD MILLION)
TABLE 9 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2017–2021 (USD MILLION)
5.12 TECHNOLOGY ANALYSIS
5.13 KEY CONFERENCES & EVENTS IN 2022–2023
TABLE 10 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES & EVENTS
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.14.1 REVENUE SOURCES TO SHIFT TOWARD TECHNOLOGY-BASED SOLUTIONS DUE TO COVID-19
5.14.2 REVENUE TO SHIFT IN INFECTIOUS DISEASE DIAGNOSTICS MARKET
5.15 KEY STAKEHOLDERS & BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 25 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS
TABLE 11 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS (%)
5.15.2 BUYING CRITERIA
FIGURE 26 KEY BUYING CRITERIA FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS
TABLE 12 KEY BUYING CRITERIA FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS
5.16 CASE STUDY
FIGURE 27 CASE STUDY: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOUR IN INDIA
6 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (Page No. – 84)
6.1 INTRODUCTION
TABLE 13 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 14 PRICES OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS (2021)
6.2 REAGENTS, KITS, AND CONSUMABLES
6.2.1 RECURRENT PURCHASES OF REAGENTS, KITS, AND CONSUMABLES TO PROPEL MARKET GROWTH
TABLE 15 INFECTIOUS DISEASE DIAGNOSTIC REAGENTS, KITS, AND CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3 INSTRUMENTS
6.3.1 INCREASING NEED FOR FASTER AND MORE ACCURATE TEST RESULTS TO BOOST INSTRUMENTS DEMAND
TABLE 16 KEY INSTRUMENTS AVAILABLE IN MARKET
TABLE 17 INFECTIOUS DISEASE DIAGNOSTIC INSTRUMENTS MARKET, BY REGION, 2020–2027 (USD MILLION)
6.4 SOFTWARE & SERVICES
6.4.1 GROWING UPTAKE OF ADVANCED INSTRUMENTS TO DRIVE SEGMENT GROWTH
TABLE 18 INFECTIOUS DISEASE DIAGNOSTIC SOFTWARE & SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
7 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING (Page No. – 91)
7.1 INTRODUCTION
TABLE 19 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2020–2027 (USD MILLION)
7.2 LABORATORY TESTING
7.2.1 RISING INCIDENCE OF VARIOUS INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
TABLE 20 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY REGION, 2020–2027 (USD MILLION)
7.3 POC TESTING
7.3.1 INCREASING ADOPTION OF POC TECHNOLOGIES TO DRIVE SEGMENT GROWTH
TABLE 21 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY REGION, 2020–2027 (USD MILLION)
7.3.2 GLOBAL POC TESTING MARKET, BY END USER
TABLE 22 GLOBAL POC TESTING MARKET FOR INFECTIOUS DISEASES, BY END USER, 2020–2027 (USD MILLION)
TABLE 23 GLOBAL TESTS ADMINISTERED BY HEALTH PROFESSIONALS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020–2027 (USD MILLION)
TABLE 24 GLOBAL CONSUMER SELF-TESTING MARKET FOR INFECTIOUS DISEASES, BY REGION, 2020–2027 (USD MILLION)
TABLE 25 US: POC TESTING MARKET FOR INFECTIOUS DISEASES, BY END USER, 2020–2027 (USD MILLION)
7.3.3 POC TESTING MARKET FOR INFECTIOUS DISEASES BY POINT OF PURCHASE AND POINT OF RESULT
TABLE 26 US: POC TESTING MARKET FOR INFECTIOUS DISEASES, BY POINT OF PURCHASE AND POINT OF RESULT, 2020-2027 (USD MILLION)
8 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. – 97)
8.1 INTRODUCTION
8.2 PRIMARY NOTES
8.2.1 KEY INDUSTRY INSIGHTS
TABLE 27 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
8.3 IMMUNODIAGNOSTICS
8.3.1 RISING PREVALENCE OF INFECTIOUS DISEASES AND DEMAND FOR RAPID DIAGNOSTIC KITS TO DRIVE MARKET GROWTH
TABLE 28 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY REGION, 2020–2027 (USD MILLION)
8.3.2 IMMUNODIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY TYPE
TABLE 29 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY TYPE, 2020–2027 (USD MILLION)
8.4 PCR
8.4.1 EMERGENCE OF ADVANCED TECHNOLOGIES SUCH AS QRT-PCR TO SUPPORT MARKET GROWTH
TABLE 30 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2020–2027 (USD MILLION)
8.5 CLINICAL MICROBIOLOGY
8.5.1 GROWING ADOPTION BY RESEARCHERS AND ACADEMIA TO DRIVE MARKET GROWTH
TABLE 31 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY REGION, 2020–2027 (USD MILLION)
8.6 INAAT
8.6.1 COST BENEFITS OF INAAT TO DRIVE MARKET GROWTH
TABLE 32 MOLECULAR DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2020–2027 (USD MILLION)
8.7 DNA SEQUENCING & NGS
8.7.1 INCREASING USE OF NGS IN CANCER DIAGNOSIS TO FUEL MARKET GROWTH
TABLE 33 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2020–2027 (USD MILLION)
8.8 DNA MICROARRAY
8.8.1 GROWING AWARENESS ABOUT ADVANCED TECHNOLOGIES TO DRIVE MARKET GROWTH
TABLE 34 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAY, BY REGION, 2020–2027 (USD MILLION)
8.9 OTHER TECHNOLOGIES
TABLE 35 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2020–2027 (USD MILLION)
9 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE (Page No. – 106)
9.1 INTRODUCTION
TABLE 36 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
9.2 COVID-19
9.2.1 OUTBREAK OF COVID-19 PANDEMIC TO DOMINATE MARKET SHARE
TABLE 37 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR COVID-19, BY REGION, 2020–2027 (USD MILLION)
TABLE 38 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR COVID-19, BY REGION, 2020–2027 (MILLION TESTS)
TABLE 39 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR COVID-19, BY METHOD, 2020–2027 (USD MILLION)
9.3 HEPATITIS
9.3.1 INCREASING ADOPTION OF ADVANCED TECHNOLOGIES FOR HEPATITIS B DIAGNOSIS TO DRIVE SEGMENT GROWTH
TABLE 40 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2020–2027 (USD MILLION)
TABLE 41 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2020–2027 (MILLION TESTS)
TABLE 42 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY METHOD, 2020–2027 (USD MILLION)
9.4 HIV
9.4.1 HIGH GLOBAL PREVALENCE TO DRIVE SEGMENT GROWTH
TABLE 43 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY REGION, 2020–2027 (USD MILLION)
TABLE 44 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY REGION, 2020–2027 (MILLION TESTS)
9.5 HOSPITAL-ACQUIRED INFECTIONS
9.5.1 RISING BURDEN OF MRSA INFECTIONS TO DRIVE SEGMENT GROWTH
TABLE 45 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HAIS, BY REGION, 2020–2027 (USD MILLION)
TABLE 46 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HAIS, BY REGION, 2020–2027 (MILLION TESTS)
9.6 MOSQUITO-BORNE DISEASES
9.6.1 INCREASING INCIDENCE OF DENGUE TO DRIVE MARKET GROWTH
TABLE 47 MAJOR PRODUCTS: DENGUE TESTING
TABLE 48 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY REGION, 2020–2027 (USD MILLION)
9.7 HPV
9.7.1 TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET GROWTH
TABLE 49 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY REGION, 2020–2027 (USD MILLION)
TABLE 50 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY REGION, 2020–2027 (MILLION TESTS)
9.8 CHLAMYDIA TRACHOMATIS
9.8.1 GROWING INCIDENCE OF CHLAMYDIA AND RISING AWARENESS AMONG PATIENTS TO DRIVE MARKET GROWTH
TABLE 51 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CT, BY REGION, 2020–2027 (USD MILLION)
TABLE 52 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CT, BY REGION, 2020–2027 (MILLION TESTS)
9.9 NEISSERIA GONORRHEA
9.9.1 RISING INCIDENCE OF GONORRHEA AND GROWING FUNDING FOR R&D TO DRIVE MARKET GROWTH
TABLE 53 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NG, BY REGION, 2020–2027 (USD MILLION)
9.10 TUBERCULOSIS
9.10.1 INCREASING BURDEN OF TUBERCULOSIS GLOBALLY TO DRIVE MARKET GROWTH
TABLE 54 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY REGION, 2020–2027 (USD MILLION)
TABLE 55 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY REGION, 2020–2027 (MILLION TESTS)
TABLE 56 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY METHOD, 2020–2027 (USD MILLION)
9.11 INFLUENZA
9.11.1 RISING FOCUS ON CONTROLLING INFLUENZA TO DRIVE MARKET GROWTH
TABLE 57 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY REGION, 2020–2027 (USD MILLION)
TABLE 58 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY REGION, 2020–2027 (MILLION TESTS)
TABLE 59 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY METHOD, 2020–2027 (USD MILLION)
9.12 SYPHILIS
9.12.1 GROWING ADOPTION OF NOVEL TECHNOLOGIES TO SUPPORT MARKET GROWTH
TABLE 60 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY REGION, 2020–2027 (USD MILLION)
9.13 OTHER INFECTIOUS DISEASES
TABLE 61 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2020–2027 (USD MILLION)
10 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER (Page No. – 124)
10.1 INTRODUCTION
TABLE 62 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
10.2 DIAGNOSTIC LABORATORIES
10.2.1 INCREASING OUTSOURCING TO DIAGNOSTIC LABORATORIES FOR REDUCED COSTS TO LED TO LARGEST MARKET SHARE
TABLE 63 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
10.3 HOSPITALS & CLINICS
10.3.1 INCREASING ADOPTION OF DIAGNOSTIC TOOLS TO SUPPORT MARKET GROWTH
TABLE 64 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2020–2027 (USD MILLION)
10.4 ACADEMIC RESEARCH INSTITUTES
10.4.1 FOCUS ON DEVELOPING INNOVATIVE TESTS TO DRIVE MARKET GROWTH
TABLE 65 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
10.5 OTHER END USERS
TABLE 66 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION)
11 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION (Page No. – 130)
11.1 INTRODUCTION
TABLE 67 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2020–2027 (USD MILLION)
11.2 NORTH AMERICA
FIGURE 28 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT
TABLE 68 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 69 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 70 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 71 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 72 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.2.1 US
11.2.1.1 Increasing prevalence of infectious diseases to drive market growth
TABLE 73 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 74 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 75 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 76 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.2.2 CANADA
11.2.2.1 Focus on affordable tests to drive market growth
TABLE 77 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 78 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 79 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 80 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3 EUROPE
TABLE 81 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 82 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 83 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 84 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 85 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.1 GERMANY
11.3.1.1 Increasing healthcare expenditure to drive market growth
TABLE 86 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 87 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 88 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 89 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.2 UK
11.3.2.1 Growing number of accredited diagnostic laboratories to propel market growth
TABLE 90 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 91 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 92 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 93 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.3 FRANCE
11.3.3.1 Rising R&D expenditure and increasing demand for early diagnosis to drive market growth
TABLE 94 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 95 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 96 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 97 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.4 ITALY
11.3.4.1 Adoption of advanced diagnostic technologies to drive market growth
TABLE 98 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 99 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 100 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 101 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.5 SPAIN
11.3.5.1 Rising geriatric population to drive market growth
TABLE 102 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 103 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 104 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 105 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.3.6 REST OF EUROPE
TABLE 106 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 107 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 108 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 109 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4 ASIA PACIFIC
FIGURE 29 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT
TABLE 110 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 111 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 112 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 113 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 114 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.1 CHINA
11.4.1.1 Growing public access to modern healthcare to drive market growth
TABLE 115 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 116 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 117 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 118 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.2 JAPAN
11.4.2.1 Universal healthcare reimbursement policy to drive market growth
TABLE 119 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 120 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 121 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 122 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.3 INDIA
11.4.3.1 Increasing private & public investments in healthcare system to drive market growth
TABLE 123 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 124 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 125 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 126 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.4.4 REST OF ASIA PACIFIC
TABLE 127 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 128 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 129 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 130 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.5 LATIN AMERICA
11.5.1 RISING DISEASE PREVALENCE AND HEALTHCARE EXPENDITURE TO DRAW FOREIGN PLAYERS
TABLE 131 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 132 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 133 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 134 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
11.6 MIDDLE EAST & AFRICA
11.6.1 RISING ACCESS TO ADVANCED TECHNOLOGIES AND GROWING INVESTMENTS TO SUPPORT MARKET GROWTH
TABLE 135 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 136 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 137 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2020–2027 (USD MILLION)
TABLE 138 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION)
12 COMPETITIVE LANDSCAPE (Page No. – 175)
12.1 OVERVIEW
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
12.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS
TABLE 139 OVERVIEW OF STRATEGIES DEPLOYED BY KEY INFECTIOUS DISEASE DIAGNOSTIC MANUFACTURING COMPANIES
12.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 30 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN INFECTIOUS DISEASE DIAGNOSTICS MARKET
12.4 MARKET SHARE ANALYSIS
12.4.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET
FIGURE 31 INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2021)
TABLE 140 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DEGREE OF COMPETITION
12.5 COMPANY EVALUATION QUADRANT
12.5.1 LIST OF EVALUATED VENDORS
12.5.2 STARS
12.5.3 EMERGING LEADERS
12.5.4 PERVASIVE PLAYERS
12.5.5 PARTICIPANTS
FIGURE 32 INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021
12.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/ SMES (2021)
12.6.1 PROGRESSIVE COMPANIES
12.6.2 STARTING BLOCKS
12.6.3 RESPONSIVE COMPANIES
12.6.4 DYNAMIC COMPANIES
FIGURE 33 INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2021
12.7 COMPETITIVE BENCHMARKING
12.7.1 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS
FIGURE 34 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF TOP PLAYERS IN INFECTIOUS DISEASE DIAGNOSTICS MARKET
TABLE 141 INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS
TABLE 142 COMPANY PRODUCT & SERVICE FOOTPRINT
TABLE 143 COMPANY REGIONAL FOOTPRINT
TABLE 144 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES
12.8 COMPETITIVE SCENARIO
12.8.1 PRODUCT LAUNCHES
TABLE 145 KEY PRODUCT LAUNCHES & REGULATORY APPROVALS
12.8.2 DEALS
TABLE 146 KEY DEALS
13 COMPANY PROFILES (Page No. – 187)
(Business overview, Products offered, Recent Developments, MNM view)*
13.1 KEY PLAYERS
13.1.1 ABBOTT LABORATORIES
TABLE 147 ABBOTT LABORATORIES: BUSINESS OVERVIEW
FIGURE 35 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2021)
TABLE 148 PRODUCT LAUNCHES & APPROVALS
13.1.2 F. HOFFMANN-LA ROCHE LTD.
TABLE 149 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
FIGURE 36 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2021)
13.1.3 THERMO FISHER SCIENTIFIC INC.
TABLE 150 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
FIGURE 37 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021)
13.1.4 SIEMENS HEALTHINEERS AG
TABLE 151 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW
FIGURE 38 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2021)
13.1.5 BIOMÉRIEUX SA
TABLE 152 BIOMÉRIEUX SA: BUSINESS OVERVIEW
FIGURE 39 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2021)
13.1.6 DANAHER CORPORATION
TABLE 153 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 40 DANAHER CORPORATION: COMPANY SNAPSHOT (2021)
13.1.7 HOLOGIC, INC.
TABLE 154 HOLOGIC, INC.: BUSINESS OVERVIEW
FIGURE 41 HOLOGIC, INC.: COMPANY SNAPSHOT (2021)
13.1.8 BECTON, DICKINSON AND COMPANY
TABLE 155 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
FIGURE 42 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021)
13.1.9 PERKINELMER, INC.
TABLE 156 PERKINELMER, INC.: BUSINESS OVERVIEW
FIGURE 43 PERKINELMER, INC.: COMPANY SNAPSHOT (2021)
13.1.10 SEEGENE, INC.
TABLE 157 SEEGENE, INC.: BUSINESS OVERVIEW
FIGURE 44 SEEGENE, INC.: COMPANY SNAPSHOT (2021)
13.1.11 QUIDEL CORPORATION
TABLE 158 QUIDEL CORPORATION: BUSINESS OVERVIEW
FIGURE 45 QUIDEL CORPORATION: COMPANY SNAPSHOT (2021)
13.1.12 QIAGEN N.V.
TABLE 159 QIAGEN N.V.: BUSINESS OVERVIEW
FIGURE 46 QIAGEN N.V.: COMPANY SNAPSHOT (2021)
13.1.13 DIASORIN S.P.A
TABLE 160 DIASORIN S.P.A: BUSINESS OVERVIEW
FIGURE 47 DIASORIN S.P.A: COMPANY SNAPSHOT (2021)
13.1.14 BIO-RAD LABORATORIES, INC.
TABLE 161 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
FIGURE 48 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2021)
13.1.15 GRIFOLS S.A.
TABLE 162 GRIFOLS S.A.: BUSINESS OVERVIEW
FIGURE 49 GRIFOLS S.A.: COMPANY SNAPSHOT (2021)
13.1.16 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC
TABLE 163 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC: BUSINESS OVERVIEW
FIGURE 50 ORTHO CLINICAL DIAGNOSTICS HOLDINGS PLC: COMPANY SNAPSHOT (2021)
13.1.17 SYSMEX CORPORATION
TABLE 164 SYSMEX CORPORATION: BUSINESS OVERVIEW
FIGURE 51 SYSMEX CORPORATION: COMPANY SNAPSHOT (2021)
13.2 OTHER PLAYERS
13.2.1 MERIDIAN BIOSCIENCE
13.2.2 ORASURE TECHNOLOGIES
13.2.3 CO-DIAGNOSTICS
13.2.4 CHEMBIO DIAGNOSTIC SYSTEMS
13.2.5 TRINITY BIOTECH PLC
13.2.6 GENETIC SIGNATURES LTD.
13.2.7 EPITOPE DIAGNOSTICS
13.2.8 TRIVITRON HEALTHCARE
13.2.9 ELITECHGROUP
13.2.10 MERIL LIFESCIENCES PVT. LTD.
13.2.11 INBIOS INTERNATIONAL
13.2.12 UNIOGEN OY
13.2.13 VELA DIAGNOSTICS
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
14 APPENDIX (Page No. – 287)
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 AVAILABLE CUSTOMIZATIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
